239 related articles for article (PubMed ID: 26856599)
21. CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.
Wissing MD; Coenen JL; van den Berg P; Westgeest HM; van den Eertwegh AJ; van Oort IM; Bos MM; Bergman AM; Hamberg P; Ten Tije AJ; Los M; Lolkema MP; de Wit R; Gelderblom H
Int J Cancer; 2015 Mar; 136(6):E760-72. PubMed ID: 25242736
[TBL] [Abstract][Full Text] [Related]
22. Abiraterone acetate in castration-resistant prostate cancer.
Iacovelli R; Palazzo A; Procopio G; Gazzaniga P; Cortesi E
Anticancer Drugs; 2012 Mar; 23(3):247-54. PubMed ID: 22123334
[TBL] [Abstract][Full Text] [Related]
23. [Advanced Prostate Cancer Consensus Conference (APCCC) 2015 in St. Gallen : Critical review of the recommendations on diagnosis and therapy of metastatic prostate cancer by a German expert panel].
Thomas C; Bögemann M; König F; Machtens S; Schostak M; Steuber T; Heidenreich A
Urologe A; 2016 Jun; 55(6):772-82. PubMed ID: 26820660
[TBL] [Abstract][Full Text] [Related]
24. [Cabazitaxel--a next-generation taxane for the treatment of patients with metastatic castration-resistant prostate cancer].
Ecstein-Fraisse E; Su Z
Gan To Kagaku Ryoho; 2014 Jul; 41(7):817-22. PubMed ID: 25131866
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer.
Galletti G; Leach BI; Lam L; Tagawa ST
Cancer Treat Rev; 2017 Jun; 57():16-27. PubMed ID: 28527407
[TBL] [Abstract][Full Text] [Related]
26. Novel strategies in the treatment of castration-resistant prostate cancer (Review).
Marech I; Vacca A; Ranieri G; Gnoni A; Dammacco F
Int J Oncol; 2012 May; 40(5):1313-20. PubMed ID: 22322981
[TBL] [Abstract][Full Text] [Related]
27. Tubulin-targeted agents including docetaxel and cabazitaxel.
Cheetham P; Petrylak DP
Cancer J; 2013; 19(1):59-65. PubMed ID: 23337758
[TBL] [Abstract][Full Text] [Related]
28. Diving Into Cabazitaxel's Mode of Action: More Than a Taxane for the Treatment of Castration-Resistant Prostate Cancer Patients.
Mellado B; Jimenez N; Marin-Aguilera M; Reig O
Clin Genitourin Cancer; 2016 Aug; 14(4):265-70. PubMed ID: 26827258
[TBL] [Abstract][Full Text] [Related]
29. Suppression of Taxanes Cytotoxicity by Citrus Flavonoid Hesperetin in PPC-1 Human Prostate Cancer Cells.
Sak K; Lust H; Kase M; Saar M; Jaal J
Anticancer Res; 2018 Nov; 38(11):6209-6215. PubMed ID: 30396939
[TBL] [Abstract][Full Text] [Related]
30. Biomarkers of response to advanced prostate cancer therapy.
Iacovelli R; Ciccarese C; Schinzari G; Rossi E; Maiorano BA; Astore S; D'Angelo T; Cannella A; Pirozzoli C; Teberino MA; Pierconti F; Martini M; Tortora G
Expert Rev Mol Diagn; 2020 Feb; 20(2):195-205. PubMed ID: 31986925
[No Abstract] [Full Text] [Related]
31. Reactive oxygen species induction by cabazitaxel through inhibiting Sestrin-3 in castration resistant prostate cancer.
Kosaka T; Hongo H; Miyazaki Y; Nishimoto K; Miyajima A; Oya M
Oncotarget; 2017 Oct; 8(50):87675-87683. PubMed ID: 29152111
[TBL] [Abstract][Full Text] [Related]
32. Current and emerging therapies for neuroendocrine prostate cancer.
Alabi BR; Liu S; Stoyanova T
Pharmacol Ther; 2022 Oct; 238():108255. PubMed ID: 35905791
[TBL] [Abstract][Full Text] [Related]
33. Resistance Mechanisms to Taxanes and PARP Inhibitors in Advanced Prostate Cancer.
Lombard AP; Gao AC
Curr Opin Endocr Metab Res; 2020 Feb; 10():16-22. PubMed ID: 32258820
[TBL] [Abstract][Full Text] [Related]
34. Improved survival in second-line advanced prostate cancer treated with cabazitaxel.
Nat Rev Clin Oncol; 2010 Dec; 7(12):671. PubMed ID: 21542197
[No Abstract] [Full Text] [Related]
35. Detection of AR-V7 mRNA in whole blood may not predict the effectiveness of novel endocrine drugs for castration-resistant prostate cancer.
Takeuchi T; Okuno Y; Hattori-Kato M; Zaitsu M; Mikami K
Res Rep Urol; 2016; 8():21-5. PubMed ID: 26870716
[TBL] [Abstract][Full Text] [Related]
36. Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.
Vignani F; Bertaglia V; Buttigliero C; Tucci M; Scagliotti GV; Di Maio M
Cancer Treat Rev; 2016 Mar; 44():61-73. PubMed ID: 26907461
[TBL] [Abstract][Full Text] [Related]
37. Managing Metastatic Castration-Resistant Prostate Cancer in the Pre-chemotherapy Setting: A Changing Approach in the Era of New Targeted Agents.
Zafeiriou Z; Jayaram A; Sharp A; de Bono JS
Drugs; 2016 Mar; 76(4):421-30. PubMed ID: 26873496
[TBL] [Abstract][Full Text] [Related]
38. Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study.
Sun Y; Zou Q; Sun Z; Li C; Du C; Chen Z; Shan Y; Huang Y; Jin J; Ye ZQ; Xie L; Lin G; Feng Y; De Porre P; Liu W; Ye D
Int J Urol; 2016 May; 23(5):404-11. PubMed ID: 26879374
[TBL] [Abstract][Full Text] [Related]
39. Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer.
Morris MJ; Rathkopf DE; Novotny W; Gibbons JA; Peterson AC; Khondker Z; Ouatas T; Scher HI; Fleming MT
Clin Cancer Res; 2016 Aug; 22(15):3774-81. PubMed ID: 26858312
[TBL] [Abstract][Full Text] [Related]
40. Potential Role for YB-1 in Castration-Resistant Prostate Cancer and Resistance to Enzalutamide Through the Androgen Receptor V7.
Shiota M; Fujimoto N; Imada K; Yokomizo A; Itsumi M; Takeuchi A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26857528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
